Showing results (1-10 of 21) with videos related to
Sort By:
Pageof 3
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|December 28, 2017
The Gut Microbiome in Neuromyelitis OpticaScott S Zamvil, Collin M Spencer, Sergio E Baranzini, et al.Annals of Neurology|July 12, 2016
Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringensBruce A C Cree, Collin M Spencer, Michel Varrin-Doyer, et al.Neurology(R) Neuroimmunology & Neuroinflammation|August 2, 2020
Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MSSarah Harris, Jonathan Q Tran, Harry Southworth, et al.Neurology(R) Neuroimmunology & Neuroinflammation|March 5, 2015
Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarateCollin M Spencer, Elizabeth C Crabtree-Hartman, Klaus Lehmann-Horn, et al.Neurology(R) Neuroimmunology & Neuroinflammation|November 25, 2015
Glatiramer acetate treatment negatively regulates type I interferon signalingNicolas Molnarfi, Thomas Prod'homme, Ulf Schulze-Topphoff, et al.Neurology(R) Neuroimmunology & Neuroinflammation|March 31, 2016
CNS accumulation of regulatory B cells is VLA-4-dependentKlaus Lehmann-Horn, Sharon A Sagan, Ryan C Winger, et al.Annals of Neurology|July 19, 2012
Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporterMichel Varrin-Doyer, Collin M Spencer, Ulf Schulze-Topphoff, et al.Journal of Visualized Experiments : Jove|September 6, 2017
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4Sharon A Sagan, Andrés Cruz-Herranz, Collin M Spencer, et al.BMC Neurology|September 23, 2016
Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controlsHelen Tremlett, Douglas W Fadrosh, Ali A Faruqi, et al.Neurology(R) Neuroimmunology & Neuroinflammation|October 6, 2016
Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progressionMichel Varrin-Doyer, Kara L Pekarek, Collin M Spencer, et al.Pageof 3